Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T-cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T-cells.

To help researchers develop efficient CAR T-cells, we aim to provide many innovative solutions, such as recombinant cell line expressing cancer antigens, or recombinant versions of these antigens. Developed by BPS Bioscience, these products will help scientists to more precisely monitor the effectiveness of the engineered CAR T to detect and bind to a specific cancer antigen.

For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development. Scientists need access to a broade range of products ( Active Enzyme, inhibitors/activators, Biochemical screening assays…), to simplify their research and identification of HDAC inhibitors.

As mentioned in a previous post the DAX Biochips from AIM Biotech are an innovative and versatile microfluidic platform, allowing researchers to more easily develop 3D cell culture models, to work as close as possible to what occurs in the human body, but under in-vitro conditions.

Due to its innovative structure (as seen in this general AIM Chips flyer), a broad range of applications have already been validated on this model (Cellular Migration-Invasion Analysis / Angiogenesis studies / Metstasis Modeling System), but what’s new is that now Immunotherapy and T-Cell Therapy studies can be performed on this technology.

TIGIT:CD155/CD112 immune inhibition (in green)

Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer treatment most of the Immunotherapeutic successes, are molecules developed to modulate and restore immune response by targeting critical Immune Checkpoints.

Some of them can activate T Cells, and on the opposite, some can inhibit this response against cancer cells, such as PD-1 and CTLA4, two of the most studied Immune Checkpoints. The majority of the popular molecules approved in Immunotherapy which have led to clinical benefits, are antibodies inhibiting immune checkpoint activities, such for PD1 with nivolumab and pembrolizumab, or CTLA4 with ipilumab.